Hitgen Inc. Class A
SSSE:68822237.08
CNY
+1.88
(+5.34%)
ISIN
CNE1000040G3
Return %
Stock
S&P 500
1Y
62.56
14.39
3Y
170.26
81.42
5Y
43.72
68.62
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jin Li
- Full Time Employees
- 546
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Chengdu China
- IPO Date
- Apr 16, 2020
- Website
- hitgen.com
- Similar Companies
- Business
- HitGen Inc. Class A is a biopharmaceutical and contract research platform company that specializes in early-stage small molecule and nucleic acid drug discovery services and proprietary pipeline development. Founded in 2012 and headquartered in Chengdu, China, the company provides discovery research solutions to pharmaceutical companies, biotechnology enterprises, and academic institutions across North America, Europe, and Asia-Pacific. HitGen organizes its core business around integrated drug discovery platforms, offering DNA-encoded chemical library (DEL) technology services, including the design, synthesis, and screening of proprietary combinatorial libraries containing over 1.2 trillion small molecules and macrocyclic peptides; self-screening and open-access DEL research products, including DELopen and DELight screening kits; fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) services, featuring protein crystallography, surface plasmon resonance (SPR), nuclear magnetic resonance (NMR), and cryo-electron microscopy; targeted protein degradation (TPD) platforms for the generation and characterization of PROTAC molecules and molecular glues; synthetic and medicinal chemistry services, encompassing route optimization, custom synthesis, and hit-to-lead development; oligonucleotide and nucleic acid research services, including siRNA, antisense oligonucleotide (ASO), and targeted ligand-oligonucleotide conjugate development; artificial intelligence-enabled and computer-aided drug design (CADD) platforms for virtual screening and predictive molecular modeling; and comprehensive in vitro biological assay development, target validation, and early ADME/PK characterization. The company conducts global operations through research and development centers in China and the United Kingdom, operating its European drug discovery hub through its wholly owned subsidiary Vernalis (R&D) Ltd, alongside business development representations in the United States. In recent developments, HitGen has accelerated the expansion of its covalent and macrocyclic DEL screening libraries, advanced multiple strategic drug discovery collaborations and target licensing agreements with multinational pharmaceutical partners, expanded its technological capabilities in oligonucleotide delivery and AI-integrated screening platforms, and broadened its overseas research infrastructure and laboratory capacities to support global biopharmaceutical client pipelines.